Acurx Pharmaceuticals (NASDAQ:ACXP) Shares Down 6.2% – Time to Sell?

Shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) dropped 6.2% during mid-day trading on Wednesday . The stock traded as low as $1.34 and last traded at $1.36. 151,805 shares traded hands during mid-day trading, an increase of 111% from the average session volume of 71,957 shares. The stock had previously closed at $1.45.

Analyst Ratings Changes

Several research firms have commented on ACXP. Wall Street Zen raised shares of Acurx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals Stock Performance

The stock’s 50-day simple moving average is $1.75 and its two-hundred day simple moving average is $2.45. The stock has a market cap of $6.45 million, a price-to-earnings ratio of -0.37 and a beta of -2.05.

Acurx Pharmaceuticals (NASDAQ:ACXP) last issued its quarterly earnings results on Tuesday, May 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.59) by ($0.03). As a group, research analysts predict that Acurx Pharmaceuticals, Inc. will post -1.94 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of ACXP. Armistice Capital LLC acquired a new stake in shares of Acurx Pharmaceuticals in the second quarter worth $551,000. Geode Capital Management LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter valued at $31,000. Jane Street Group LLC acquired a new position in Acurx Pharmaceuticals during the 4th quarter valued at $27,000. Finally, Millennium Management LLC bought a new stake in Acurx Pharmaceuticals in the 4th quarter valued at $103,000. 11.53% of the stock is currently owned by institutional investors and hedge funds.

About Acurx Pharmaceuticals

Acurx Pharmaceuticals, Inc, headquartered in King of Prussia, Pennsylvania, is a clinical?stage biopharmaceutical company focused on the discovery and development of novel anti?infective therapies. The company’s research platform leverages insights into bacterial virulence regulation and quorum sensing pathways to design small-molecule candidates aimed at reducing pathogen toxicity and biofilm formation. By targeting key mechanisms of infection rather than bacterial viability alone, Acurx seeks to offer differentiated treatment options that may help address the growing challenge of antibiotic resistance.

Acurx’s lead product candidates are being developed to treat acute bacterial skin and skin structure infections (ABSSSI), including cases caused by drug-resistant strains such as methicillin-resistant Staphylococcus aureus (MRSA).